中新网深圳2月4日电 (记者 索有为)4日，中国科学院深圳先进技术研究院(简称"深圳先进院")集成所研 究员徐天添团队联合浙江大学研究员陆豪健团队在《自然—传感器》上发表最新研究。合作团队开发出 了一种可贴附、可定制的柔性磁定位贴片系统，并构建了"双阶段磁定位"策略，有望为微创手术中医疗 器械的操作提供高精度、实时跟踪的新策略。 可定制的柔性磁定位贴片。研究团队供图 近年来，磁场定位技术被逐渐引入医疗领域，展现出了巨大的应用潜力，可实时追踪手术器械的位置， 为医生提供精准的操作指引，助力提升手术精准性和成功率。传统的磁定位系统依赖固定、刚性的外部 传感器或大型电磁装置，缺乏部署灵活性并受空间限制，难以适应复杂多变的临床操作环境。 基于这种柔性贴片，研究人员进一步开发出了双阶段定位算法，它就像卫星导航系统中的"基站辅助定 位"功能，首先通过外部磁场，确定柔性贴片在全局坐标系中的位置，再以该贴片作为局部参考，实现 对体内小型磁性目标的定位。 在血管介入手术、消化道内镜手术、辅助手术机器人等微创手术中，对医疗器械进行实时、精准的三 维"导航"，是保障手术安全与操作效率的重要基础。CT、MRI和数字减影血管造影(DS ...

1月18日，据武汉经开区消息，武汉协和医院智能脑机接口研究院将落户车谷院区。据悉，智能脑机接 口研究院将致力于侵入式和非侵入式脑机接口关键核心技术研究，建成国内首个脑机接口专病智能体矩 阵，构建百万级多模态脑病数据库，完成多项脑机接口医疗器械临床试验，孵化培育一批掌握核心技 术、具有市场竞争力的脑机接口科技型企业。 ...

Group 1 - The Shenzhen Eye Hospital, led by Professor Chi Wei, presented a report on "From Eye to Brain: The Path of Implantable Brain-Machine Interface for Visual Reconstruction" at the Fifth Frontier of Brain Science and Industry Conference [1] - The research team successfully implanted a wireless, multi-channel visual cortex prosthesis in non-human primates, marking a significant advancement in brain-machine interface technology [3] - This implant is the smallest semi-invasive brain-machine interface visual implant globally, causing minimal trauma and risk, and it successfully induced neuronal discharge in the visual cortex [3] Group 2 - Since 2020, Shenzhen Eye Hospital has collaborated with Shenzhen Zhongke Xianjian Medical Technology Co., focusing on the development of artificial retinal prostheses and visual cortex prostheses, with successful animal testing [5] - The research is expected to lead to clinical-grade products within the next three years, demonstrating a significant leap from eye to brain technology [5] - The brain-machine interface industry is a key focus area for the Shenzhen Eye Hospital's "Eye-Brain Laboratory," aiming to integrate advancements in brain visual science, artificial intelligence, and biochips [8]

Core Points - The establishment of the Suzhou Integration Development Center by the Chinese Microcirculation Society aims to enhance the management of chronic diseases and promote innovation in the biomedicine industry in Suzhou [1][2] - The center will focus on technology transfer, professional talent training, and the development of technical standards in the field of chronic disease screening and prevention [1] - The collaboration between the Chinese Microcirculation Society, Suzhou Science and Technology Association, and Southeast University Suzhou Research Institute is aligned with the strategic needs of high-quality development in the biomedicine sector and the "Healthy Suzhou" initiative [1] Group 1 - The center's establishment is expected to gather top expert resources and cutting-edge technological achievements to facilitate breakthroughs in microcirculation-related disease prevention and control, high-end medical device research and development, and optimization of chronic disease management systems [1] - The center aims to significantly enhance the demonstration and leading effect of "Science and Technology Innovation China" in Suzhou [1] - Since its founding in 1993, the Chinese Microcirculation Society has been deeply involved in academic research, clinical transformation, and industry-education integration in the microcirculation field [2] Group 2 - The society has established strong academic foundations and rich expert resources in areas such as cardiovascular and cerebrovascular diseases, diabetic complications, tumor microenvironments, and tissue engineering [2] - In the current year, the society has organized over 60 experts to engage with 39 local biomedicine companies and 24 research institutions and hospitals in Suzhou, resulting in 15 cooperation intentions [2] - The society has also provided professional technical guidance to 10 local enterprises [2]

Core Insights - A new eye implant system has been developed that can help 80% of patients with age-related macular degeneration partially regain their vision [1][2] - Age-related macular degeneration is the leading cause of blindness globally, particularly affecting individuals over 60 years old [1] - The system, named Prima, consists of a retinal implant and augmented reality glasses, designed to replace lost photoreceptor cells due to the disease [2] Group 1 - The Prima system includes a 2mm x 2mm retinal implant that is 30 micrometers thick, which is surgically placed beneath the retina [2] - The augmented reality glasses are equipped with a mini camera that captures images and processes them through a computer to enhance contrast and brightness before projecting them as infrared light onto the retinal implant [2] - Clinical trials involved 38 patients with severe vision impairment, with 32 completing the study [2] Group 2 - After one year of using the Prima system, 81% of participants could read at least 10 more letters on a vision chart, and 78% could read at least 15 more letters [2] - The best-performing participant was able to read 59 additional letters, and 84.4% of participants reported being able to read letters, numbers, and words [2] - A total of 26 serious adverse events were observed among 19 participants, all of which were anticipated risks, including high intraocular pressure and subretinal hemorrhage, with most resolving on their own or through medical intervention [2]

Core Viewpoint - Zhejiang University School of Medicine's Shao Yifu Hospital has developed the world's first biodegradable bone glue, "Bone 02," inspired by the adhesion mechanism of oysters, which can bond bone fragments effectively in a blood environment [1][2]. Summary by Sections Product Development - "Bone 02" is designed to bond bone fragments in various fracture types, potentially reducing or replacing traditional metal fixation methods [1]. - The development team conducted rigorous clinical trials over eight months, involving over 150 patients, demonstrating good safety and efficacy [1][2]. Technical Aspects - The material consists of a liquid phase and a solid phase, both of which are biocompatible and consist of components already present in the human body [3]. - The adhesive mechanism allows for rapid solidification within three minutes, creating a strong bond with bone tissue [4]. Performance Metrics - Key performance indicators include adhesion strength, operational time, and biocompatibility, which were optimized through extensive testing and iterations [5]. - The final formulation allows for a 3 to 5-minute operational window before solidification begins, ensuring sufficient time for precise application during surgery [5]. Clinical Advantages - Compared to traditional metal fixation, "Bone 02" reduces surgical time, minimizes tissue trauma, and accelerates recovery [11]. - The product's biodegradable nature eliminates the need for secondary surgeries to remove metal implants, thus reducing overall healthcare costs [15]. Future Applications - The technology is expected to shift orthopedic surgery paradigms from mechanical fixation to biological healing, with potential applications in various fields, including dental implants and spinal surgery [19][20]. - "Bone 02" is anticipated to be approved for widespread clinical use within the next two to three years [20]. Emergency Use - The product's simplicity and rapid application make it suitable for emergency situations, such as battlefield or disaster scenarios, where quick stabilization of injuries is critical [18].

Core Viewpoint - The development of a new bone adhesive material named "Bone 02" by Zhejiang University Shao Yifu Hospital shows promising results in treating comminuted fractures, demonstrating good safety and efficacy in clinical trials involving over 150 patients [1][2]. Group 1: Product Development - The "Bone 02" material was inspired by the biological adhesion mechanism of oysters and underwent over 50 formula iterations and hundreds of tests to overcome key challenges such as biotoxicity and adhesion strength in blood environments [2]. - The maximum adhesive pull force of "Bone 02" can reach over 400 pounds, indicating its potential to replace traditional metal fixation devices while reducing the risk of foreign body reactions and infections [2]. Group 2: Clinical Application - The new adhesive material is applicable for fixing bone fragments of various sizes and can significantly enhance surgical efficiency and reduce trauma during operations, contributing to minimally invasive orthopedic surgeries [2]. - "Bone 02" is expected to be useful in emergency situations such as military operations and disaster rescue, where rapid and effective fracture treatment is critical [2].

Core Viewpoint - The establishment of the Zero Magnetic Interventional Medicine Laboratory at Fudan University Affiliated Pudong Hospital represents a significant advancement in the integration of zero magnetic medicine and advanced interventional medicine, aiming for early non-invasive diagnosis of diseases with high precision and resolution [1][2]. Group 1: Laboratory Establishment and Collaboration - The Zero Magnetic Interventional Medicine Laboratory is led by Fudan University Affiliated Pudong Hospital and integrates resources from several prestigious hospitals and universities, forming a high-level academic team and a complete innovation transformation chain from theoretical research to technology development and industrial application [1]. - A four-party strategic cooperation agreement was signed among Fudan University Affiliated Pudong Hospital, Beihang University Large Scientific Device Research Institute, Hangzhou Weak Magnetic Field National Major Science and Technology Infrastructure Research Institute, and related enterprises [1]. Group 2: Technological Advancements and Research Focus - Academician Fang Jiancheng emphasized that weak magnetic fields are a new scientific discovery that complements structural imaging technologies, aiming to build a comprehensive health detection system for the human body [2]. - The laboratory will focus on the research and development of intelligent zero magnetic interventional materials and devices, establish clinical technical guidelines, and cultivate high-level talent, ultimately creating a national-level center for the promotion and application of zero magnetic interventional medicine technology [2]. Group 3: Future Directions and Benefits - The laboratory aims to enhance the deep research and application promotion of zero magnetic technology in interventional medicine, strengthening interdisciplinary collaboration and results transformation [3]. - The collaboration is expected to provide better early screening and treatment options for cardiac and brain diseases, benefiting a larger population [2].

Core Viewpoint - Huaborn Neutron Technology Co., Ltd. has completed a multi-hundred million RMB Pre-A round financing, indicating strong market confidence in Boron Neutron Capture Therapy (BNCT) as a promising treatment method [2][11]. Company Overview - Established in 2023 and headquartered in Hangzhou, Zhejiang, Huaborn Neutron is a national high-tech enterprise focused on the research, production, and application of accelerator-driven BNCT technology [3]. - The company was founded by Wang Sheng, a renowned neutron scientist, and has assembled a team of experts across various disciplines including nuclear physics, software, control, mechanics, pharmacy, clinical medicine, and materials science [3]. Main Products and Technologies - Huaborn Neutron has developed the HyBorSys® BNCT full-process solution, which includes an accelerator neutron source system, boron drugs, and a treatment planning system (TPS), achieving a complete closed-loop for BNCT technology [4]. - The BNCT equipment utilizes a high-current proton RFQ accelerator and long-life solid lithium target technology, ensuring high power stability and a target lifespan that is globally leading (>1500 mA·h) [6]. - The company has established a research and development system for boron drug synthesis, significantly improving product quality and reducing production costs [7]. - The domestically developed TPS can model based on multi-modal imaging data from patients, simulating dose distribution using Monte Carlo particle transport programs for precise prediction and individualized treatment planning [9]. Current Status and Future Prospects - The HyBorSys® demonstration device has completed medical device registration inspection, and the boron drug is about to enter the IND application stage [10]. - BNCT is recognized as a significant breakthrough in the field of radiotherapy, gradually moving towards clinical application, with Huaborn Neutron achieving independent breakthroughs in devices, drugs, and software within two years [11]. - The recent financing round, attracting several hundred million RMB, reflects the capital market's high recognition of BNCT as a cutting-edge therapy [11].

Employment Market Overview - The employment rate for individuals aged 16-64 in the UK rose to 75.1% from February to April 2025, indicating a positive aspect of the job market [1] - However, the number of salaried employees decreased by 55,000 (0.2%) in March-April 2025 and by 115,000 (0.4%) from April 2024 to April 2025, suggesting a cautious hiring strategy among UK businesses [1][3] Public vs. Private Sector Employment - Public sector employment remained stable at 6.15 million in March 2025, with a year-on-year growth of 0.6%, while private sector employment growth faced different challenges [3] - This disparity provides insights for investors, indicating that stable public sector-related industries may offer defensive investment opportunities, while emerging sectors in the private sector also hold potential [3] Unemployment and Economic Inactivity - The unemployment rate for individuals aged 16 and above reached 4.6% from February to April 2025, showing an increase both year-on-year and quarter-on-quarter, which raises concerns about economic growth [3] - The economic inactivity rate for those aged 16-64 decreased to 21.3%, but a significant portion is attributed to long-term illness and students, highlighting structural issues in the labor market [3] Wage Growth and Job Vacancies - Average wage growth for employees was notable, with regular wages increasing by 5.2% and total wages by 5.3% from February to April 2025, leading to improved consumer purchasing power [4] - Job vacancies fell to 736,000 from March to May 2025, marking a continuous decline over 35 quarters, indicating weakened labor demand and cautious investment in labor-intensive sectors [4] Consumer Sector Opportunities - With rising wages, the consumer sector is expected to experience growth, particularly in mid-to-high-end consumption areas such as premium retail, quality dining, and personalized travel services [5] - UK high-end fashion brands may benefit from increased disposable income, leading to higher sales, while specialty tourism projects and luxury hotels are also likely to gain from the consumption upgrade trend [5] Healthcare Sector Investment Potential - The high proportion of long-term illness in the economically inactive population underscores pressure on the UK healthcare system, presenting investment opportunities in medical device development and biopharmaceuticals focused on chronic disease treatment [6] Education and Training Sector Growth - The shortage of skilled labor in the UK is driving demand for education and training, particularly in vocational skills training and online education platforms, which are poised for significant growth [7] Human Resources Services Demand - Despite an overall decline in job vacancies, there remains a strong demand for high-end and specialized talent recruitment, suggesting that human resources service firms focusing on high-end talent acquisition may thrive [8]